Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02019758|
Recruitment Status : Completed
First Posted : December 24, 2013
Results First Posted : April 26, 2019
Last Update Posted : May 15, 2019
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response.
Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized.
Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims
|Condition or disease||Intervention/treatment||Phase|
|Eosinophilic Esophagitis||Drug: Oral Viscous Budesonide Drug: Fluticasone MDI Drug: Placebo slurry Drug: Placebo inhaler||Phase 4|
This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing oral viscous budesonide (OVB) to fluticasone metered dose inhaler (MDI) for treatment of EoE. A total of 122 subjects aged 16-80 years old will be randomized in a 1:1 fashion to one of two active treatment arms: OVB + placebo inhaler or fluticasone MDI + placebo slurry.
In the first arm, subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily. The OVB is a slurry equivalent to what is used clinically: 1 mg/4 mL aqueous budesonide mixed with 10 g of sucralose. Rather than asking the subjects to mix the slurry on their own and risk inconsistent formulations, the University of North Carolina (UNC) investigational drug pharmacy (IDP) will provide pre-mixed OVB to all patients. The IDP will also provide placebo inhalers to all patients. The dose for OVB has been chosen because it is the most commonly studied dose, including one prior study led by this Principal Investigator, so we can accurately estimate response rates.
In the second arm, subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB. The UNC investigational drug pharmacy (IDP) will provide the fluticasone MDIs and pre-mixed placebo slurries to all patients. The dose for fluticasone MDI has been chosen because this is the most commonly used dose in adolescents and adults with EoE, so effect estimates are also available.
For both arms, the slurry will be administered first, the MDI will be administered 15 minutes later, and patients will take nothing by mouth for an additional 30 minutes.
Subjects will receive 8 weeks of treatment and will then be monitored for up to 52 weeks for recurrence of symptoms.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||129 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis|
|Actual Study Start Date :||January 1, 2015|
|Actual Primary Completion Date :||May 2018|
|Actual Study Completion Date :||April 2019|
Active Comparator: Oral Viscous Budesonide (OVB)
Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
Drug: Oral Viscous Budesonide
Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
Other Name: Pulmicort
Drug: Placebo inhaler
Placebo inhaler - 4 puffs twice daily
Other Name: Placebo
Active Comparator: Active Fluticasone MDI
Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
Drug: Fluticasone MDI
Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
Other Name: Flovent
Drug: Placebo slurry
Slurry of sucralose - 4 mL twice daily
Other Name: Sucralose
- Post-treatment Maximum Eosinophil Count (Aim 1) [ Time Frame: 8 weeks ]To determine whether viscous budesonide is more effective than fluticasone MDI for improving post-treatment maximum esophageal eosinophil counts (measured in eosinophils per high powered field (eos/hpf)) in patients with eosinophilic esophagitis (EoE). The mean post-treatment maximum eosinophil count will be compared between the OVB and MDI groups using a two-sample t-test.
- Post-treatment Dysphagia Score (Aim 1) [ Time Frame: 8 weeks ]To determine whether viscous budesonide is more effective than fluticasone MDI for improving dysphagia (measured by the Daily Symptoms Questionnaire (DSQ)) in patients with EoE. The mean DSQ scores will be compared between the OVB and MDI groups using a two-sample t-test. The DSQ is a dysphagia severity score which ranges from 0-84, with higher numbers indicating more severe symptoms.
- Post-treatment Endoscopic Severity (Aim 1) [ Time Frame: 8 weeks ]Endoscopic severity will be quantified using the EoE Endoscopic Reference Score (EREFS) and compared between the two treatment arms. EREFS is a validated endoscopic severity score of key EoE endoscopic features (exudates, rings, edema, furrows, and strictures), and ranges from 0-9 with higher scores indicating higher endoscopic severity.
- Percentage of Participants With Histologic Response of <15 Eos/Hpf [ Time Frame: 8 weeks ]Percentage with histologic response, with response defined as <15 eos/hpf, will be compared between groups
- Post-treatment Symptom Severity (Aim 1) [ Time Frame: 8 weeks ]Post-treatment symptoms severity will be assessed with the EoE Symptom Activity Index (EEsAI), a validated dysphagia severity measure. The EEsAI ranges from 0-100, with higher scores indicating more severe symptoms; symptom remission is defined by a score <20.
- Post-treatment Medication Compliance (Aim 1) [ Time Frame: 8 weeks ]Medication compliance as measured by the percentage of medication appropriately used in each arm. For the slurry, this percentage is calculated after measuring the residual volume. For the inhaler, this percentage is calculated after measured using the residual weight.
- Symptom Recurrence (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]To test whether OVB results in less symptomatic recurrence than fluticasone MDI, survival analysis will be performed with the interval between treatment end (week 8) and recurrent symptoms or study end (week 60) as the time of interest. A Kaplan-Meier curve will be constructed comparing the time until symptom recurrence in both study groups using the log-rank test.
- Histologic Recurrence (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]To test whether OVB results in less histologic recurrence than fluticasone MDI, the proportion of subjects with ≥15 eos/hpf at follow-up endoscopy in each group will be compared using chi-square.
- Endoscopic Severity at Recurrence (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]Measurement of endoscopic severity, using the validated EREFS measure, at the time of recurrence
- Peak Eosinophil Count (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]This will assess the level of esophageal eosinophilia on biopsy (measured in peak eosinophil count - eos/hpf) at the time of recurrence
- Baseline Immunohistochemical (IHC) Staining and Histologic Response (Aim 3) [ Time Frame: Enrollment (Day 1) ]
To determine whether baseline immunohistochemical (IHC) staining of esophageal biopsies for major basic protein (MBP), eotaxin-3, and mast cell tryptase (MCT) is associated with histologic response in EoE patients treated with topical corticosteroid therapy. The mean baseline cellular staining for each biomarker (MBP, eotaxin-3, and MCT) will be compared between the responder and non-responder groups using a two-sample t-test.
Note: Results are not yet available for this outcome, as these samples will be batch processed together with other histologic data being collected for this trial which may be collected up until 1 year after completing the initial 8-week treatment and are still being collected.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02019758
|United States, North Carolina|
|University of North Carolina, Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Evan S Dellon, MD, MPH||University of North Carolina, Chapel Hill|